Showing 139 news articles about Injectable & long-acting HIV treatment

Filters Content type: Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

TB treatment

Should TB Treatment Move into Long-Acting Injectables?

Editor's pick
Contagion Live
11 March 2021
Injectable & long-acting HIV treatment

ViiV Seeks FDA Approval for Cabenuva Dosed Every 2 Months for HIV

Editor's pick
Monthly Prescribing Reference
26 February 2021
Injectable & long-acting HIV treatment

Cabenuva, the First Long-Acting Injectable HIV Regimen, Is Here; Now, Who Will Take It?

Editor's pick
TheBody
29 January 2021
Injectable & long-acting HIV treatment

Previous Intravenous Drug Use May Impact Women's Comfort With Injectable HIV Medications

Editor's pick
American Journal of Managed Care
25 January 2021
Injectable & long-acting HIV treatment

FDA approves first long-acting injectable to treat HIV infection

Editor's pick
STAT
22 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Editor's pick
ViiV Healthcare press release
22 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Editor's pick
ViiV Healthcare press release
21 December 2020
Injectable & long-acting HIV treatment

A Long-Lasting, More Effective HIV Drug Is A Psychological Relief For Patients

Editor's pick
NPR
20 November 2020
Injectable & long-acting HIV treatment

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Editor's pick
ViiV Healthcare press release
16 October 2020
Injectable & long-acting HIV treatment

ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices

Editor's pick
ViiV press release
4 July 2020
Injectable & long-acting HIV treatment

GSK says it is within weeks of resubmitting HIV injection Cabenuva

Editor's pick
Reuters
3 July 2020
New & experimental HIV treatments

Experimental HIV drug seems effective at a twice-a-year dose, study finds

Editor's pick
STAT
2 July 2020
Injectable & long-acting HIV treatment

Women With HIV Interested in Long-Acting Injectable Treatment

Editor's pick
POZ
4 May 2020
Injectable & long-acting HIV treatment

Health Canada okays GSK unit's monthly HIV injection

Editor's pick
Reuters
23 March 2020
Injectable & long-acting HIV treatment

Unitaid invests in long-acting medicines to simplify treatment and prevention for HIV, TB, malaria and HCV

Editor's pick
Unitaid
7 February 2020
Injectable & long-acting HIV treatment

No holiday gift for GSK: FDA sends long-acting HIV injectable back to work

Editor's pick
FiercePharma
24 December 2019
Injectable & long-acting HIV treatment

FDA Defers Approval of First Long-Acting HIV Therapy, Surprising Everyone

Editor's pick
HIV and ID Observations
23 December 2019
HIV treatment

Top 10 HIV Clinical Developments of 2019

Editor's pick
TheBodyPro
27 November 2019
New & experimental HIV treatments

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational "bNAb" with potential for long-acting HIV treatment and prevention

Editor's pick
ViiV Healthcare press release
21 November 2019
Injectable & long-acting HIV treatment

Women Find Long-Acting Injectable ART 'Emotionally Freeing and Empowering'

Editor's pick
Contagion Live
7 October 2019
Injectable & long-acting HIV treatment

HIV implant targets disease for up to a year

Editor's pick
The Engineer
26 September 2019
PrEP science

Long-acting injectable multi-drug implant shows promise for HIV prevention and treatment

Editor's pick
EurekAlert
23 September 2019
Injectable & long-acting HIV treatment

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Editor's pick
DURECT press release
6 August 2019
People with limited treatment options

Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
2 August 2019